对于中东人口的炎症性肠病的先进疗法的使用和现实世界的有效性:系统性审查
Mohammed Nabil Quraishi1,2,3, Maryam A Alahmad4, Ala I Sharara5
1Department of Gastroenterology, Sheikh Shakhbout Medical City, Abu Dhabi, UAE moquraishi@ssmc.ae.
BMJ open gastroenterology
|December 2, 2025
概括
现实世界的证据表明,先进的疗法对中东的炎症性肠病 (IBD) 有效. 然而,研究设计的多样性限制了强有力的结论,需要强有力的区域数据收集以获得更好的治疗指南.
科学领域:
- 胃肠病学 胃肠病学
- 临床药理学 临床药理学
- 现实世界的证据.
背景情况:
- 炎症性肠病 (IBD) 管理正在随着先进疗法的发展而发展.
- 对于这些疗法在中东人口中存在的有限的现实世界证据 (RWE).
研究的目的:
- 系统地审查RWE关于IBD中东患者先进治疗方法的有效性和利用情况.
- 综合该地区生物制剂和小分子的现有数据.
主要方法:
- 对观察性RWE研究的系统审查.
- 搜索了主要数据库,截至2025年5月.
- 包括成人和儿科IBD患者;不包括RCT和小病例系列.
主要成果:
- 包括来自中东的23项研究,主要是沙特阿拉伯和伊朗.
- 抗TNF疗法显示出不同的有效性;乌斯特基努马布显示出强烈的有效性.
- 像瑞桑基祖马布和托法西提尼布这样的新药在特定队列中显示出有前途.
结论:
- 先进的治疗方法在中东的IBD群体中似乎有效.
- 研究设计和报告中的显著异质性限制了最终的结论.
- 需要有前性,协作性的区域注册表,以提高证据质量,并为当地指导方针提供信息.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
450
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
450
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
413
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
413
Drugs for Treatment of Ulcerative Colitis in IBD
431
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
431
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
617
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
617
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
461
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
461
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
457
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
457


